Mini Case study on Merck/Vioxx

User Generated

Pelfgny18

Writing

User generated content is uploaded by users for the purposes of learning and should be used following Studypool's honor code & terms of service.

Explanation & Answer

Attached.

Running Head: MINI CASE STUDY ON MERCK OUTLINE

Mini Case Study on Merck OUTLINE
Name
Institutional Affiliation

1

MINI CASE STUDY ON MERCK OUTLINE
Introduction and Summary


The article “Earlier Merck Study Indicated Risks of Vioxx” by Meier and published in
The New York Times on 2004 is a well-written piece that depicts how Merck was
irresponsible in banning the use of Vioxx drug despite having preliminary results
showing that the painkiller posed cardiovascular risks.



Relying on a well-researched point of view, Meier manages to portray that Merck failed
to disclose the results of the separate study that had raised a concern about the safety
records of Vioxx.

Critical Reflections


In the article, the dominant purpose is to depict how Merck was irresponsible in
disclosing the separate reports that indicated that Vioxx posed cardiovascular risks.



All the facts presented by Meier (2004) are intended to justify that Merck did not pay
huge attention to the safety issues of the Vioxx.



Using systematic review and reports from the UnitedHealth Group, Meier (2004)
indicated that Vioxx posed an increased risk of cardiovascular problems.

Research Methods


Meier (2004) used qualitative and quantitative research methods to conduct the study.



The qualitative methods used in the article include observations, interviews, and case
studies.



The quantitative methods used in the article include insight reports, government
information, and secondary data obtained from Merck.

2

MINI CASE STUDY ON MERCK OUTLINE

3

Strengths and Weakness of the Article


In terms of strengths, the article relies on ...


Anonymous
Great study resource, helped me a lot.

Studypool
4.7
Trustpilot
4.5
Sitejabber
4.4

Related Tags